Vir Biotechnology: The Low-Down On The Readouts Ahead [Seeking Alpha]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Seeking Alpha
VIR-5500's upcoming ASCO GU update offers an opportunity to show what VIR-5500 can do, since previous data was fairly early on in dose escalation work. Additional readouts from the hepatitis delta work, from ECLIPSE 2 and ECLIPSE 3, are expected in Q1'27. Meaning VIR could have five readouts in the next 12 months. Rasi Bhadramani/iStock via Getty Images Vir Biotechnology ( VIR ) is developing drugs for both hepatitis delta and oncology indications. I last wrote about VIR in March 2025, when I noted the company had a promising set of drugs with This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of VIR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past perfor
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
- Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.MarketBeat
- Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 11/5/25 - Miss
VIR
Sec Filings
- 2/3/26 - Form 4
- 1/14/26 - Form 144
- 1/12/26 - Form 8-K
- VIR's page on the SEC website